✦ LIBER ✦

Evaluation of Treatment Response in Patients with Metastatic Renal Cell Carcinoma: Role of State-of-the-Art Cross-Sectional Imaging

✍ Scribed by Venkata S. Katabathina; Nathalie Lassau; Ivan Pedrosa; Chaan S. Ng; Srinivasa R. Prasad

Book ID: 107555450
Publisher: Springer
Year: 2011
Tongue: English
Weight: 754 KB
Volume: 13
Category: Article
ISSN: 1527-2737
DOI: 10.1007/s11934-011-0233-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The role of surgery in clinical manageme

The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma

✍ Thomas Steiner; Hartmut Kirchner; Michael Siebels; Christian Doehn; Hans Heynema 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 270 KB

Response of renal lesions during systemi

Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients

✍ C. Seidel; M. Fenner; A. S. Merseburger; C. Reuter; P. Ivanyi; F. Länger; A. Gan 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 434 KB

Erythrocyte sedimentation rate kinetics

Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib

✍ Hai-Liang Zhang; Yao Zhu; Chao-Fu Wang; Xu-Dong Yao; Shi-Lin Zhang; Bo Dai; Yi-J 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 620 KB

A population-based study evaluating the

A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer

✍ Daniel Y. C. Heng; Kim N Chi; Nevin Murray; Tao Jin; Jorge A Garcia; Ronald M Bu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 1 views

## Abstract ## BACKGROUND: Sunitinib has replaced interferon (IFN) as a first‐line standard of care in the treatment of metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients. ## METH

The use of polyethylene glycol-modified

The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma

✍ James C. Yang; Suzanne L. Topalian; Douglas J. Schwartzentruber; David R. Parkin 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 707 KB

Editorial Comment to Erythrocyte sedimen

Editorial Comment to Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib

✍ Ying Wu; Yulan Zhao 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB